Praziquantel - Isotope Labelled Standards
References
FAQ's
References
- Seubert, Juergen; Thomas, Herbert; Andrews, Peter, Pyrazino-Isoquinoline Derivatives, Merck Patent G.m.b.H., United States, GB1441554A, July 7, 1976
- Diekmann, H. W.,Quantitative determination of praziquantel in body fluids by gas liquid chromatography, European Journal of Drug Metabolism and Pharmacokinetics, Volume: 4, Issue: 3, Pages: 139-41,1979
Frequently Asked Questions
How are Praziquantel impurities managed during manufacturing?
Planning and optimization of Praziquantel's synthetic method minimizes impurity formation. Reaction parameters of temperature, pressure, and reaction time are under strict control to minimize impurity production. Side reactions and impurity production reduce by optimizing reaction conditions. Throughout the production process, stringent quality control mechanisms are in place.
Can Praziquantel impurities change over time?
Yes, the impurities in Praziquantel can alter over time. A pharmaceutical product's stability, including its formation and degradation, can be impacted by storage conditions, temperature, humidity, light exposure, and the chemical characteristics of the therapeutic ingredient.
Which solvent is used for the analysis of Praziquantel impurities?
The solvent used to analyze Praziquantel impurities might vary based on the studies of the individual impurity and its analytical method.
What are the temperature conditions required to store Praziquantel impurities?
Praziquantel impurities should be stored at a controlled room temperature of 2-8°C or as described on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.